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Background: There is no consensus on the indication for salvage chemoradiotherapy (CRT) after failure of primary
chemotherapy for locally advanced pancreatic cancer (LAPC). Here we report on the retrospective analysis of
patients who received salvage CRT after primary chemotherapy for LAPC. The primary objective of this study was to
evaluate the efficacy and safety of salvage CRT after primary chemotherapy for LAPC.
Methods: Thirty patients who underwent salvage CRT, after the failure of primary chemotherapy for LAPC, were
retrospectively enrolled from 2004 to 2011 at the authors’ institution. All the patients had histologically confirmed
pancreatic adenocarcinoma.
Results: Primary chemotherapy was continued until progression or emergence of unacceptable toxicity. Eventually,
26 patients (87%) discontinued primary chemotherapy because of local tumor progression, whereas four patients
(13%) discontinued chemotherapy because of interstitial pneumonitis caused by gemcitabine. After a median
period of 7.9 months from starting chemotherapy, 30 patients underwent salvage CRT combined with either S-1 or
5-FU. Toxicities were generally mild and self-limiting. Median survival time (MST) from the start of salvage CRT was
8.8 months. The 6 month, 1-year and 2-year survival rates from the start of CRT were 77%, 33% and 26%,
respectively. Multivariate analysis revealed that a lower pre-CRT serum CA 19–9 level (≤ 1000 U/ml; p = 0.009) and a
single regimen of primary chemotherapy (p = 0.004) were independent prognostic factors for survival after salvage
CRT. The MST for the entire patient population from the start of primary chemotherapy was 17.8 months, with
2- and 3-year overall survival rates of 39% and 22%, respectively.
Conclusions: CRT had moderate anti-tumor activity and an acceptable toxicity profile in patients with LAPC, even
after failure of gemcitabine-based primary chemotherapy. If there are any signs of failure of primary chemotherapy
without distant metastasis, salvage CRT could be a treatment of choice as a second-line therapy. Patients with
relatively low serum CA19-9 levels after primary chemotherapy may achieve higher survival rates after salvage CRT.
The strategy of using chemotherapy alone as a primary treatment for LAPC, followed-by CRT with salvage intent
should be further investigated in prospective clinical trials.
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The prognosis of pancreatic cancer remains dismal. The
5-year overall survival of patients with pancreatic cancer
is < 5%. In Japan, about 27,000 patients are estimated to
have pancreatic cancer, and almost the same numbers of
deaths annually are attributable to this cancer. Although
surgical resection offers the opportunity for cure, less
than 20% of patients are diagnosed with pancreatic cancer
at an early resectable stage. At initial diagnosis, ≥ 80% of
patients with pancreatic cancer have locally advanced or
metastatic disease.
Locally advanced pancreatic cancer (LAPC) is defined
as surgically unresectable disease without detectable me-
tastases. Historically, concurrent chemoradiotherapy
(CRT) with 5-fluorouracil (5-FU) has been the standard
treatment since it offers survival benefit when compared
with best supportive care [1], radiotherapy alone [2] and
chemotherapy with 5-FU alone [3]. Recently, 5-FU has
been replaced by oral fluorouracil analogues such as S-1
in East Asia [4] and capecitabine in Western countries.
When taken orally these drugs are much more conveni-
ent to administer than 5-FU, which usually requires pro-
tracted venous infusion. S-1 is an oral agent that
contains tegafur, gimeracil and oteracil in a molar ratio
of 1:0.4:1 [5]. S-1 is reported to be at least equivalent to
or even more active than 5-FU when combined with
radiotherapy for LAPC [6-8].
The standard method used for the detection of metas-
tases from pancreatic cancer is computed tomography
(CT). Several investigators have reported that intrao-
perative staging can reveal occult peritoneal dissemin-
ation in 6–37% of the patients with CT-diagnosed LAPC
[9-11]. Analysis of patterns of failure after definitive
CRT for LAPC has shown that more than half of the
patient will have distant metastasis at the first time of
failure [12]. Because radiotherapy involving the primary
site offers little benefit to patients with occult distant
metastasis, increasingly more oncologists believe that
chemotherapy would be a preferable initial therapeutic
approach for patients with LAPC [13]. During ini-
tial chemotherapy, rapidly progressive chemotherapy-
resistant distant metastases will present within a few
months. After 3–6 months of induction chemotherapy,
LAPC that remained local would be an indication for
consolidative or salvage CRT. However, there is no con-
sensus on the indications for additional CRT following
primary chemotherapy for LAPC, as well as the optimal
time period for the administration of primary chemo-
therapy. Here we report on the results of a retrospective
analysis of this strategy, including primary chemotherapy
and salvage CRT, for patients with LAPC. The primary
objective of our study was to evaluate the efficacy and
safety associated with salvage CRT following primary




Between October 2004 and August 2011, 98 patients who
were diagnosed as having LAPC underwent CRT at the
author’s institution. Sixty-seven patients were excluded
from the study because they had received definitive CRT as
the first therapeutic modality. One patient was excluded
because he had undergone consolidative CRT after primary
chemotherapy. The remaining 30 patients underwent sal-
vage CRT after the failure of primary management with
chemotherapy alone. All of the patients had histologically
confirmed pancreatic adenocarcinoma. They were sub-
jected to intensive analysis. The clinical data from these
patients were entered into the database in September 2012.
Our institutional review board (Institutional Ethical Review
Board of the National Cancer Center) approved this study.
Treatment strategy
At the first diagnosis, multidetector row CT involving
the chest and abdomen were performed for the assess-
ment of the local extension of the primary tumor, and
for excluding distant metastases. CT based criteria
regarding tumor unresectability included encasement or
occlusion of the celiac trunk, common hepatic artery,
superior mesenteric artery or aorta. All of the patients
with obstructive jaundice underwent biliary drainage
prior to treatment.
Until December 2007, primary management with CRT
combined with 5-FU was the principal treatment of
choice for patients with LAPC [14]. Since 2006, several
prospective phase II clinical trials involving patients with
LAPC were conducted at the authors’ institution
[4,8,15,16]. CRT combined with S-1 has been regarded
as an optional treatment of choice in Japan [7,8]. A
multi-institutional phase II trial with gemcitabine
(GEM) alone for LAPC yielded promising results with a
low toxicity profile [15]. Additionally, our retrospective
study revealed that there was no difference in the sur-
vival rates of the patients who received CRT or GEM-
based chemotherapy alone as a primary therapy for
LAPC [17]. Although direct comparison between pri-
mary CRT and primary chemotherapy alone has not yet
been made in a prospective clinical trial, GEM mono-
therapy has been regarded as the first treatment of
choice in clinical practice since January 2008.
Currently, all of the patients with LAPC are informed
of two first-line treatments of choice, namely GEM
monotherapy and CRT combined with S-1. If a patient
with LAPC has an indication suitable for participation in
a clinical trial, the patient will be given additional infor-
mation about that trial. The patients themselves selected
Table 1 Patient characteristics (n = 30)
Characteristic No. of patients % patients
Age (years)














Baseline tumor diameter (cm)
Median (range) 4.5 (2.1-7.8)
Baseline serum CA19-9 level (U/ml)
Median (range) 872 (0–35490)
≥ 1,000 14 47
100-1,000 11 37
< 100 5 17
Pre-CRT tumor diameter (cm)
Median (Range) 4.1 (1.9-8.4)
Pre-CRT serum CA19-9 Level (U/ml)
Median 631 (0–50440)
≥ 1,000 11 37
100-1,000 12 40
< 100 7 23
Regimens of primary chemotherapy
Gemcitabine alone 24 80
Gemcitabine + α 6 20
CRT chemoradiotherapy.
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patients who initially entered prospective clinical trials
involving primary chemotherapy and who subsequently
received CRT as a salvage treatment.
Eligibility criteria for salvage CRT
Indications for salvage CRT following chemotherapy
included the following: no distant metastasis; no prior
radiotherapy of the upper abdomen; Karnofsky perform-
ance status (KPS) ≥ 70; adequate hematologic function
(leucocyte count ≥ 3,500/μL and platelet count ≥ 100,000/
μL ); and hepatic function (bilirubin ≤ 2.0 mg/dL, aspar-
tate aminotransferase (AST)/alanine aminotransferase
(ALT) ≤ 150 U/L) and renal function (serum creatinine <
1.5 mg/ml). The exclusion criteria were the presence of:
an active gastroduodenal ulcer; watery diarrhea; ascites;
active infection; or mental disorder. Written informed
consent was obtained from each patient before starting
each treatment.
First-line chemotherapy
Primary chemotherapy was continued until disease pro-
gression, the emergence of unacceptable toxicity or a
patient’s refusal of treatment. First-line chemotherapy
mostly consisted of GEM alone [Table 1]. GEM was admi-
nistered intravenously at a dose of 1,000 mg/m2 over 30
min on days 1, 8 and 15, and was repeated every 4 weeks
as one course. Patients with grade 3–4 hematological toxi-
cities underwent dose reduction to 800 mg/m2 or skipped
at least one administration of GEM. Prophylactic
granulocyte-colony stimulating factor support was not
used.
Chemoradiotherapy
A planning CT was required to determine target
volumes on the three-dimensional treatment planning
system. A total dose of 50.4 Gy was delivered in 28 frac-
tions using a linear accelerator of energy ≥ 10 MV. The
clinical target volume (CTV) included the gross primary
tumor and metastatic lymph nodes only. Elective nodal
irradiation was not applied in this cohort. The planning
target volume (PTV) was defined as the CTV plus 1 cm
in all directions and a 1.5-2.0 cm margin in the cranio-
caudal direction to account for respiratory organ mo-
tion. The dose was prescribed to the center of the PTV.
Typically, a 4 or 5 field technique was used to minimize
high-dose radiation exposure in the surrounding organs.
Radiotherapy was delivered concomitantly with either
5-FU or S-1. Protracted 5-FU infusion was mainly admi-
nistered until July 2008, and oral S-1 was given there-
after. Concomitant 5-FU was administered as a
protracted venous infusion at a dose of 200 mg/m2/day
from days 1–5 each week during the course of radiother-
apy [14]. S-1 was administered orally twice daily afterbreakfast and dinner on weekdays (Monday through Fri-
day) during irradiation. The standard dose of S-1 with
concurrent radiotherapy for LAPC was 80 mg/m2/day
[4]. Maintenance chemotherapy with S-1 was indicated
for patients without obvious clinical progression during
CRT, with sufficient performance status and organ
function.
Response and toxicity assessment
All of the medical charts of the eligible patients were
reviewed. Information on potential prognostic factors
was collected and included: age; gender; performance
status; tumor diameter; change in serum carbohydrate
Table 2 Best response to primary chemotherapy
Tumor response No. of patients % patients
Radiological response
Partial response 9 30
Stable disease 19 63
Progressive disease 2 7
CA19-9 response (base line CA19-9 > 100 U/ml)
≥ 50% decrease 21 88
< 50% decrease 1 4
Increase 2 8
Table 3 The reasons for discontinued primary
chemotherapy
Reason No. of patients % patients
Presence of any types of primary disease progression (n = 26)
Enlargement of tumor 14 47
Elevation of tumor marker 7 23
Carcinomatous pain 5 17
Obstructive jaundice 5 17
Duodenal hemorrhage 2 7
Absence of disease progression (n = 4)
Interstitial pneumonia 4 13
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ments. Contrast-enhanced CT was performed before
starting every two cycles of primary chemotherapy, be-
fore and at the end of CRT, and every 2 months after
CRT. Objective tumor response was evaluated radio-
logically according to the Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.1 [18]. CA19-9 was
continuously measured once per month. Toxicities were
prospectively recorded at each patient’s visit using the
Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0. The highest grades of toxicity
observed during CRT and after CRT were recorded.
Statistical analysis
Overall survival from the start of primary chemotherapy
and salvage CRT was estimated using the Kaplan-Meier
method. Times to progression at the primary tumor site
or distant sites were also calculated. Progression was
defined as confirmation of progressive disease on CT
images using the RECIST criteria. For univariate and
multivariate analysis, all of the variables were dichoto-
mized according to clinical relevance based on the previ-
ous literature. Univariate analyses were performed using
the log-rank test. A Cox’s proportional hazards model
was developed to identify significant factors influencing
survival after CRT. Possible confounded variables were
excluded from multivariate analysis. All of the tests of
hypotheses were conducted at an alpha level of 0.05 with
a 95% confidence interval (CI). All of the statistical ana-
lyses were performed using SPSS Statistics version 17.0
(SAS Institute, Tokyo, Japan).
Results
Patient characteristics
Thirty patients with LAPC received primary chemother-
apy and salvage CRT. The patient characteristics are
summarized in [Table 1]. For first-line chemotherapy, all
of the patients received GEM-based chemotherapy.
GEM-based chemotherapy included GEM alone in 24
patients (80%) and GEM-based combination chemother-
apy in six patients (20%).
Sequel of first-line chemotherapy
The median number of cycles of GEM in 24 patients
who received GEM monotherapy was six (range, 1–41).
Best tumor response assessed radiologically and best
CA19-9 response to first-line chemotherapy are sum-
marized in Table 2. A partial response (PR) was achieved
in nine patients, with a response rate of 30%. Among 24
patients whose baseline serum CA19-9 level was >100
U/ml, the median CA19-9 level decreased from 1151 U/
ml at baseline to 159 U/ml at minimum during first-line
chemotherapy. In these patients, the CA19-9 level
decreased by ≥ 50% in 21 patients (88%); the mediantime to reach the minimum CA19-9 level was 4.0 (range,
1.8-13.0) months. After failure of first-line GEM-based
chemotherapy, seven patients (23%) proceeded to
second-line chemotherapy with S-1 alone. The median
duration of continuing second-line chemotherapy was
3.0 months.
Eventually, 26 patients (87%) discontinued primary
chemotherapy because of local tumor progression,
whereas four patients (13%) discontinued chemotherapy
because of interstitial pneumonitis caused by GEM. The
reasons for discontinuation of the primary chemother-
apy are summarized in Table 3.
Sequence of salvage CRT
Thirty patients started salvage CRT after the failure of
the primary chemotherapy. The median time between
the start of the primary chemotherapy and the start of
CRT was 7.9 (range, 3.0-37.3) months. All of the patients
completed the course of radiotherapy without major
interruption. The median duration of CRT was 42
(range, 38–45) days. Administration of the combined
chemotherapeutic agents involved protracted infusion of
5-FU in 14 patients (47%) and oral S-1 in 16 patients
(53%). Toxicities during and after CRT are listed in
Table 4. Hematological toxicity was relatively mild and
there was no grade 4 toxicity. The most frequent grade 3
hematological toxicity was leucopenia. Grades 3 and 4
Table 4 Toxicity during and after salvage chemoradiotherapy
Toxicity Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Toxicity of any grade (%) Toxicity of grade 3–4 (%)
Hematological toxicity
Leukopenia 6 11 11 3 0 81 10
Neutropenia 12 13 5 1 0 61 3
Anemia 4 14 10 3 0 87 10
Thrombocytopenia 12 16 3 0 0 61 0
AST/ALT 20 9 2 0 0 35 0
Non-hematological toxicity
Fatigue 7 17 5 2 0 77 6
Anorexia 4 18 3 5 1 87 19
Nausea 9 15 5 2 0 71 6
Vomiting 24 6 0 1 0 23 3
Diarrhea 21 8 2 0 0 32 0
Abdominal pain 20 9 2 0 0 35 0
Stomatitis 29 2 0 0 0 6 0
Skin rash 29 2 0 0 0 6 0
Infection 29 0 1 1 0 6 3
Gastrointestinal ulcer 27 0 2 1 1 13 6
AST aspartate transaminase, ALT alanine transaminase.
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nausea (6%), fatigue (6%), gastrointestinal ulcer (6%),
vomiting (3%) and bile duct infection (3%). After CRT,
three patients developed a gastrointestinal ulcer; of
these, two (grade 2) recovered after conservative treat-
ment, and one (grade 3) required endoscopic hemostasis.
Another patient developed a duodenal fistula involving
the primary tumor at 2 months after completion of CRT
(grade 4). This fistula was possibly caused by the necro-
sis of the huge primary tumor that penetrated the duo-
denal wall. Although the hemorrhage was transient, this
patient needed to undertake long-term fasting and intra-
venous hyperalimentation, but later died of severe bile
duct hemorrhage because of primary tumor progression.
Four patients were diagnosed as having distant metas-
tasis immediately after the completion of salvage CRT.
Because of poor general health and/or the lack of an effi-
cacious chemotherapeutic regimen, these patients did
not undergo further evaluation. The response of the pri-
mary tumor was evaluated radiologically at 2 months
after the completion of CRT in 26 patients. Tumor re-
sponse to CRT included a PR in one patient (3%), stable
disease (SD) in 22 patients (73%) and progressive disease
(PD) in three patients (10%). Among the 24 patients
whose initial CA19-9 level was >100 U/ml, the median
CA19-9 level decreased from 769 U/ml to 479 U/ml at
minimum after CRT. The CA19-9 level decreased more
than 50% in 14 patients (58%) after CRT. Relief of pain
was achieved in 16 out of 19 patients (84%) who had
experienced carcinomatous pain before CRT. After thecompletion of salvage CRT, 20 patients (67%) started
maintenance chemotherapy. Maintenance chemotherapy
mainly consisted of the S-1 based regimen. The median
duration of continued maintenance chemotherapy was 4
months.
Overall outcomes
The median overall survival time (MST) of the entire pa-
tient population from the start of salvage CRT was 8.8
(95% CI, 7.8-9.8) months. The 6 month, 1-year and
2-year survival rates from the start of salvage CRT were
76.7%, 33.3% and 26.3%, respectively (Figure 1). At the
time of analysis, four patients were still alive, while 26
patients had died of disease progression. No patients
underwent radical resection of their pancreatic cancer
after CRT. The median progression-free survival (PFS)
time from the start of salvage CRT was 4.9 (95% CI, 3.4-
6.3) months. The 6 month, 1-year and 2-year PFS rates
were 40.0%, 15.2% and 5.7%, respectively. Sites of disease
progression after CRT were documented in all 28
patients with progression; they are summarized in
Table 5. The sites of first failure after CRT included dis-
tant metastases in 17 patients (61%) and locoregional
progression in 10 patients (36%); one patient (3%) had
both sites of first failure after CRT. Although prophylac-
tic nodal irradiation was not undertaken, isolated nodal
recurrence as a first site of recurrence was observed in
only one patient. The median local progression-free time
from the start of CRT was 9.8 (95% CI, 7.2-12.3) months
(Figure 2). The 6 month, 1-year and 2-year local
Figure 1 Kaplan-Meier survival curve for overall survival from
the start of salvage chemoradiotherapy.
Figure 2 Kaplan-Meier survival curve for the local progression-
free ratio from the start of salvage chemoradiotherapy.
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spectively. The median distant metastasis-free time from
the start of CRT was 6.2 (95% CI: 2.6-9.8) months.
In two patients, the primary tumors showed no re-
sponse to primary chemotherapy and they had PD
(Table 2). The primary tumors of these two patients
remained stable at the completion of CRT. One patient
was not evaluated further because lung metastases
emerged at the completion of CRT. She received best
supportive care owing to her poor general condition.
The primary tumor in the other patient remained stable
for 9.6 months, then progressed locally. Both patients
died of primary disease at 4.0 and 13.7 months after the
start of CRT.
Considered overall, the MST from the start of primary
chemotherapy was 17.8 (95% CI, 12.3-23.3) months. TheTable 5 Sites of first disease progression after salvage
chemoradiotherapy
Disease site No. of patients % patients
None 2 7
Distant metastases 17 57
Liver 12
Peritoneum 2
Liver and peritoneum 1
Lung 1
Liver and lung 1
Locoregional progression 10 33
Local progression 9
Regional lymph node 1
Local progression and distant metastases 1 3
Local and peritoneum 11-, 2-, 3- and 4-year survival rates from the commence-
ment of first-line chemotherapy were 83.3%, 38.8%,
21.7% and 7.2%, respectively (Figure 3).
Univariate and multivariate analysis of pre-CRT factors
influencing survival after CRT
Univariate analysis was performed on 11 different vari-
ables to evaluate their potential value in terms of sur-
vival after salvage CRT (Table 6). Significant prognostic
factors for improved survival included KPS (≥ 80; p =
0.022); number of regimens of primary chemotherapy
(single; p = 0.006); pre-CRT tumor diameter ≤ 4 cm (p =
0.04); and pre-CRT serum CA19-9 level (≤ 1000 U/ml;
p = 0.002). The absence of local progression beforeFigure 3 Kaplan-Meier survival curve for overall survival from
the start of primary chemotherapy.
Table 6 Results of univariate analysis of survival after salvage chemoradiotherapy
Factors No. of patients Median survival time (months) 6-month survival (%) 1-year survival (%) 2-year survival (%) p-value
All patients 30 8.8 77 33 26
Age
< 65 14 8.1 79 29 14
≥ 65 16 9.2 75 38 38 0.2
Gender
Male 16 8.1 75 31 25
Female 14 9.2 79 36 29 0.6
Karnofsky performance status
≥ 80 28 9.1 79 36 28
< 80 2 4.8 50 0 0 0.03
Primary tumor location
Head 15 9.4 93 40 33
Body / tail 15 8.5 60 27 18 0.5
Number of regimens of primary chemotherapy
1 25 9.4 80 40 32
2 5 6.1 60 0 0 0.006
Best response to primary chemotherapy
PR 9 9.2 89 33 33
SD or PD 21 8.5 71 33 24 0.6
Pre-chemoradiotherapy tumor diameter (cm)
≤ 4 12 10.8 83 50 50
> 4 18 8.5 72 22 0 0.04
Pre-chemoradiotherapy serum CA19-9 level (U/ml)
≤ 1,000 29 10.8 90 47 42
> 1,000 11 6.4 54 9 0 0.002
Local progression before starting chemoradiotherapy
Absent 4 NA 80 60 60
Present 26 8.8 76 28 19 0.15
Time from the start of primary chemotherapy to chemoradiotherapy
≤ 6 months 12 8.5 75 33 25
> 6 months 18 8.8 78 33 28 0.9
Combined chemoradiotherapy agents
5-FU 14 7.2 64 21 14
S-1 16 9.9 88 44 37 0.09
PR partial response, SD stable disease, PD progressive disease, NA not available.
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ing salvage CRT (p = 0.09) were not significant prognos-
tic factors. The time from the start of primary
chemotherapy to salvage CRT was not associated with
survival (p = 0.73). Using multivariate analysis, a lower
pre-CRT serum CA-19-9 level (≤ 1000 U/ml; p = 0.009)
and a single regimen of primary chemotherapy (p =
0.004) were found to be independent prognostic factors
for survival after salvage CRT (Table 7).Discussion
In the present study, the MST of the entire patient
population from the start of salvage CRT was 8.8
months. The median time to local progression from the
commencement of salvage CRT was 8.9 months. Before
starting CRT, all of the patients experienced failure of
the primary chemotherapy. However, the MST of 8.8
months for this cohort is comparable to the historical
MST achieved after primary CRT combined with 5-FU
Table 7 Results of multivariate analysis of survival after
salvage chemoradiotherapy










Number of regimens of
primary chemotherapy
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similar [13]. In addition, the frequency of grade 3–4
non-hematological toxicity observed in the current study
was also similar to that reported in previous studies.
These findings show that CRT combined with S-1 or 5-
FU had moderate anti-tumor activity and an acceptable
toxicity profile in patients with LAPC, even after failure
of GEM-based primary chemotherapy.
In the literature, the representative MST of patients
with LAPC who were included in prospective clinical
trials was reported to be 8.4-11.4 months for 5-FU-
based CRT [2,3,14,19], 9.2-15.0 months for GEM mono-
therapy [15,20] and 10.3-11.1 months for GEM-based
CRT [20,21]. Generally, only a few patients with LAPC
survive for 3 years or more. The MST from salvage CRT
in our cohort seems to be inferior to those reported in
recent studies involving primary therapy for LAPC.
However, if we consider primary chemotherapy and sal-
vage CRT as a combined treatment strategy, the MST of
17.8 months from the start of primary chemotherapy is
a promising result. Additionally, long-term survivors
from the start of primary chemotherapy in our cohort
seem to be distinct, with 22% achieving a 3-year overall
survival. In our cohort, only patients who underwent
primary chemotherapy and progressed locally without
distant metastases were selected to receive salvage CRT.
Because of the strong selection bias, we should not com-
pare this outcome to that of prospective clinical trials in
the literature. However, the existence of long-term survi-
vors in our cohort suggests that salvage CRT should
have some benefit in selected patients with LAPC, even
after failure of the primary chemotherapy. The strategy
of using chemotherapy alone as a primary treatment for
LAPC, followed-by CRT for salvage intent, should be
further investigated in prospective clinical trials.
Combined with radiotherapy, S-1 has been demon-
strated to exert a synergistic effect against 5-FU-resistant cancer xenografts [22]. We previously con-
ducted a phase I trial to determine the maximum toler-
ated dose of S-1 with concurrent radiotherapy for LAPC
[4]. This dose was 80 mg/m2/day, which is the same as
the full dose of S-1 when administered alone. The tox-
icity of CRT combined with S-1 for LAPC was generally
mild and manageable with conservative treatment. Sev-
eral phase II clinical trials of CRT combined with S-1 for
LAPC achieved MSTs in the range 14.3-16.2 months
[7,8]. These MSTs compare favorably with the historical
MSTs reported for CRT combined with 5-FU of 8.4-11.4
months [2,14]. In the current study, either S-1 or 5-FU
was combined with radiotherapy. Univariate analysis of
survival after subsequent CRT showed a non-significant
trend towards better results when CRT was combined
with S-1 (Table 6). The occurrence of grade 3–4 non-
hematological toxicity during and after CRT was less fre-
quent among the patients who had received CRT com-
bined with S-1, as compared with 5-FU (6% versus 43%).
Because of the retrospective nature of this study, a dif-
ference in baseline characteristics may inhibit a fair
comparison between the two agents. Although a direct
comparison between S-1 and 5-FU has not yet been
undertaken in a prospective clinical trial, CRT combined
with S-1 is an attractive alternative to 5-FU-based CRT.
The value of S-1 in pancreatic cancer is not limited to
its sensitizing effect during CRT. Single agent S-1 has
excellent activity regarding chemo-naïve metastatic pan-
creatic cancer, with a response rate of 37.5% and a MST
of 9.2 months [23]. S-1 is the first agent that has not
proved inferior to GEM as a single agent for the treat-
ment of advanced pancreatic cancer in a phase III
randomized-controlled trial [16]. S-1 also retains its ac-
tivity in relation to advanced pancreatic cancer even
after the failure of GEM, with a response rate of 21%
[24]. Accordingly, in the current study, the activity of
salvage CRT with S-1 should be related to the excellent
systematic effect of the agent on subclinical distant me-
tastasis, as well as its local sensitizing effect.
Recently, induction chemotherapy has become a major
component in the treatment strategy for LAPC. Two
well-designed retrospective studies have shown that
induction chemotherapy followed by CRT yielded a
survival benefit over primary CRT or continued chemo-
therapy alone for LAPC [12,25]. More recently, several
phase II prospective clinical trials have been conducted
to evaluate the value of induction chemotherapy fol-
lowed by CRT, which resulted in MSTs in the range
12.6-19.2 months [26-28]. The optimum duration of in-
duction chemotherapy for LAPC continues to be a mat-
ter of debate. Recent prospective clinical trials that
included induction chemotherapy for LAPC had chosen
to evaluate the effects of 2–6 months of induction ther-
apy [26-28]. In the current study, the median duration
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than those used in these prospective trials. Because
patients with rapidly progressing occult-metastatic dis-
ease were excluded from the present study, the tumors
in our cohort might have deviated to relatively chemo-
responsive tumors. Therefore, the duration of primary
chemotherapy was not associated with survival after
CRT in the current study. We could not draw any con-
clusion with regard to the optimum duration of induc-
tion chemotherapy from this retrospective cohort study.
In agreement with the current study, previous studies
have shown that a highly-elevated CA 19–9 level is a
poor prognostic factor for patients who had received
CRT for LAPC [29,30]. A highly elevated serum CA19-9
level in patients prior to CRT suggests chemo-resistance
of the tumor, as well as the existence of progressive oc-
cult metastasis. These patients might gain little benefit
from the addition of salvage CRT.
Multivariate analysis revealed that the use of two regi-
mens of primary chemotherapy was an unfavorable fac-
tor for survival after CRT. The MST of the patients who
received two regimens of primary chemotherapy was 6.1
months from the start of salvage CRT, and no patient
survived for 12 months or longer thereafter (Table 6). In
all of the patients (n = 5) who underwent two regimens
of primary chemotherapy before CRT, S-1 was used as a
second-line chemotherapy. Of these patients, three
received salvage CRT combined with 5-FU, and two
received salvage CRT combined with S-1. Because both
5-FU and S-1 are fluorinated pyrimidine agents, failure
of the tumor to respond to treatment with S-1 should
cause resistance to salvage CRT combined with either 5-
FU or S-1. If there are any signs of failure to respond to
the primary chemotherapy, without distant metastasis,
salvage CRT could be a treatment of choice as a second-
line therapy.
Because of the retrospective nature of the current
study, there were a number of limitations that affected
the interpretation of our findings. The number of
patients was very limited and the patient population was
not homogeneous because of different clinical back-
grounds, and they received CRT with salvage intent.
Also, the patients were collected for over a period of 7
years, non-consecutively. The clinical response to pri-
mary chemotherapy was generally better than previously
reported, possibly because of the exclusion of patients
with chemo-resistant occult distant metastasis. Only
patients who underwent primary chemotherapy and pro-
gressed locally without distant metastases were selected
and included in the current analysis.
Whether or not the addition of chemotherapy prior to
CRT will contribute to prolonging the survival of
patients with LAPC has not been elucidated with suffi-
cient statistical power in a prospective clinical trial. Weare now investigating the value of induction chemother-
apy with GEM versus no induction chemotherapy for
LAPC in a multi-institutional randomized phase II study
involving S-1 and concurrent radiotherapy (JCOG1106,
UMIN000006811). A future phase III study will be con-
ducted to compare GEM monotherapy and S-1 based
CRT with or without induction GEM, depending on the
results of the JCOG1106 study. Another phase III study,
the GERCOR LAP 07 phase III trial (www.clinicaltrials.
gov, identifier code NCT00634725) is also ongoing. This
study was designed to elucidate the benefit of induction
chemotherapy followed by CRT combined with capecita-
bine, with or without erlotinib during induction chemo-
therapy and a CRT phase. In future, results from these
prospective clinical trials will become available to further
define the role of chemotherapy followed by CRT for
LAPC.
Conclusions
CRT combined with S-1 or 5-FU had moderate anti-
tumor activity in patients with LAPC even after failure
of GEM-based primary chemotherapy. If there are any
signs of failure to primary chemotherapy without distant
metastasis, salvage CRT could be a treatment of choice
as a second-line therapy. Patients with a relatively low
serum CA19-9 level after primary chemotherapy may
obtain additional survival benefit from salvage CRT. The
strategy of using chemotherapy alone as a primary treat-
ment for LAPC, followed-by CRT with salvage intent
should be further investigated in prospective clinical
trials.
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